Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Mapping single-cell transcriptomes in the intra-tumoral and associated territories of kidney cancer.
Li R, Ferdinand JR, Loudon KW, Bowyer GS, Laidlaw S, Muyas F, Mamanova L, Neves JB, Bolt L, Fasouli ES, Lawson ARJ, Young MD, Hooks Y, Oliver TRW, Butler TM, Armitage JN, Aho T, Riddick ACP, Gnanapragasam V, Welsh SJ, Meyer KB, Warren AY, Tran MGB, Stewart GD, Cortés-Ciriano I, Behjati S, Clatworthy MR, Campbell PJ, Teichmann SA, Mitchell TJ. Li R, et al. Among authors: welsh sj. Cancer Cell. 2022 Dec 12;40(12):1583-1599.e10. doi: 10.1016/j.ccell.2022.11.001. Epub 2022 Nov 23. Cancer Cell. 2022. PMID: 36423636 Free PMC article.
Incidence, risk factors and outcomes of checkpoint inhibitor-induced liver injury: A 10-year real-world retrospective cohort study.
Atallah E, Welsh SJ, O'Carrigan B, Oshaughnessy A, Dolapo I, Kerr AS, Kucharczak J, Lee CYC, Crooks C, Hicks A, Chimakurthi CR, Rao A, Franks H, Patel PM, Aithal GP. Atallah E, et al. Among authors: welsh sj. JHEP Rep. 2023 Jul 18;5(10):100851. doi: 10.1016/j.jhepr.2023.100851. eCollection 2023 Oct. JHEP Rep. 2023. PMID: 37727807 Free PMC article.
ETV4-Dependent Transcriptional Plasticity Maintains MYC Expression and Results in IMiD Resistance in Multiple Myeloma.
Neri P, Barwick BG, Jung D, Patton JC, Maity R, Tagoug I, Stein CK, Tilmont R, Leblay N, Ahn S, Lee H, Welsh SJ, Riggs DL, Stong N, Flynt E, Thakurta A, Keats JJ, Lonial S, Bergsagel PL, Boise LH, Bahlis NJ. Neri P, et al. Among authors: welsh sj. Blood Cancer Discov. 2024 Jan 8;5(1):56-73. doi: 10.1158/2643-3230.BCD-23-0061. Blood Cancer Discov. 2024. PMID: 37934799 Free PMC article.
Transcriptional Heterogeneity Overcomes Super-Enhancer Disrupting Drug Combinations in Multiple Myeloma.
Welsh SJ, Barwick BG, Meermeier EW, Riggs DL, Shi CX, Zhu YX, Sharik ME, Du MT, Abrego Rocha LD, Garbitt VM, Stein CK, Petit JL, Meurice N, Tafoya Alvarado Y, Fonseca R, Todd KT, Brown S, Hammond ZJ, Cuc NH, Wittenberg C, Herzog C, Roschke AV, Demchenko YN, Chen WD, Li P, Liao W, Leonard WJ, Lonial S, Bahlis NJ, Neri P, Boise LH, Chesi M, Bergsagel PL. Welsh SJ, et al. Blood Cancer Discov. 2024 Jan 8;5(1):34-55. doi: 10.1158/2643-3230.BCD-23-0062. Blood Cancer Discov. 2024. PMID: 37767768 Free PMC article.
A Systematic Review of Immune Checkpoint Inhibitors in Non-Clear-Cell Renal Cancer.
Palma Dos Reis AF, Simão D, Odeny T, Rodrigues C, Fontes-Sousa M, da Luz R, Chowdry RP, Welsh SJ, Paller C, Barata PC. Palma Dos Reis AF, et al. Among authors: welsh sj. Kidney Cancer. 2022 Aug 4;6(2):115-127. doi: 10.3233/KCA-210012. eCollection 2022. Kidney Cancer. 2022. PMID: 36212797 Free PMC article.
A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA).
Stewart GD, Welsh SJ, Ursprung S, Gallagher FA, Jones JO, Shields J, Smith CG, Mitchell TJ, Warren AY, Bex A, Boleti E, Carruthers J, Eisen T, Fife K, Hamid A, Laird A, Leung S, Malik J, Mendichovszky IA, Mumtaz F, Oades G, Priest AN, Riddick ACP, Venugopal B, Welsh M, Riddle K, Hopcroft LEM; NAXIVA Trial Group; Jones RJ. Stewart GD, et al. Among authors: welsh sj. Br J Cancer. 2022 Oct;127(6):1051-1060. doi: 10.1038/s41416-022-01883-7. Epub 2022 Jun 23. Br J Cancer. 2022. PMID: 35739300 Free PMC article. Clinical Trial.
A Randomized Phase II Study of MEDI0680 in Combination with Durvalumab versus Nivolumab Monotherapy in Patients with Advanced or Metastatic Clear-cell Renal Cell Carcinoma.
Voss MH, Azad AA, Hansen AR, Gray JE, Welsh SJ, Song X, Kuziora M, Meinecke L, Blando J, Achour I, Wang Y, Walcott FL, Oosting SF. Voss MH, et al. Among authors: welsh sj. Clin Cancer Res. 2022 Jul 15;28(14):3032-3041. doi: 10.1158/1078-0432.CCR-21-4115. Clin Cancer Res. 2022. PMID: 35507017 Free PMC article. Clinical Trial.
59 results